- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.63 Å
- Oligo State
- hetero-2-2-2-mer
- Ligands
- 4 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- NAG- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-NAG-MAN-MAN-FUC.3: 15 residues within 4Å:- Chain A: N.205, S.207, V.208, R.392, K.393
- Chain B: K.196, Y.197, R.326, F.327, G.329, K.393
- Chain D: W.34, L.35
- Ligands: NAG-NAG-BMA-MAN-MAN-FUC.6, NAG-NAG-BMA-MAN-MAN-FUC.6
5 PLIP interactions:3 interactions with chain A, 2 interactions with chain B- Hydrophobic interactions: A:K.393
- Hydrogen bonds: A:R.392, A:K.393, B:K.393, B:K.393
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-FUC.6: 17 residues within 4Å:- Chain A: K.196, Y.197, R.326, F.327, G.329, K.393
- Chain B: R.202, N.205, S.207, V.208, R.392, K.393
- Chain C: W.34, L.35
- Ligands: NAG-NAG-NAG-MAN-MAN-FUC.3, NAG-NAG-NAG-MAN-MAN-FUC.3, IOD.61
4 PLIP interactions:1 interactions with chain C, 2 interactions with chain B, 1 interactions with chain A- Hydrophobic interactions: C:L.35, B:V.208
- Water bridges: B:R.392
- Hydrogen bonds: A:K.393, C:W.34
- 89 x IOD: IODIDE ION(Non-functional Binders)
IOD.7: 3 residues within 4Å:- Chain A: R.270, T.432, T.433
Ligand excluded by PLIPIOD.8: 1 residues within 4Å:- Chain A: W.402
Ligand excluded by PLIPIOD.9: 1 residues within 4Å:- Chain A: R.300
Ligand excluded by PLIPIOD.10: 4 residues within 4Å:- Chain A: Q.89, F.101
- Chain E: E.5, H.6
Ligand excluded by PLIPIOD.11: 3 residues within 4Å:- Chain A: R.96, A.97, R.143
Ligand excluded by PLIPIOD.12: 2 residues within 4Å:- Chain A: T.192, K.374
Ligand excluded by PLIPIOD.13: 2 residues within 4Å:- Chain A: P.12, R.49
Ligand excluded by PLIPIOD.14: 5 residues within 4Å:- Chain A: R.127, E.130
- Chain C: H.97
- Ligands: IOD.46, HEM.84
Ligand excluded by PLIPIOD.15: 2 residues within 4Å:- Chain A: P.331, P.333
Ligand excluded by PLIPIOD.16: 3 residues within 4Å:- Chain A: R.326, N.360
- Chain D: R.20
Ligand excluded by PLIPIOD.17: 2 residues within 4Å:- Chain A: R.163
- Chain C: Y.9
Ligand excluded by PLIPIOD.18: 4 residues within 4Å:- Chain A: N.283, N.345, K.347, K.351
Ligand excluded by PLIPIOD.19: 1 residues within 4Å:- Chain A: P.191
Ligand excluded by PLIPIOD.20: 3 residues within 4Å:- Chain A: D.235, N.236, M.241
Ligand excluded by PLIPIOD.21: 1 residues within 4Å:- Chain A: K.26
Ligand excluded by PLIPIOD.22: 3 residues within 4Å:- Chain A: T.112, Q.297
- Ligands: NAG-NAG.2
Ligand excluded by PLIPIOD.23: 2 residues within 4Å:- Chain A: A.40
- Ligands: IOD.47
Ligand excluded by PLIPIOD.24: 2 residues within 4Å:- Chain A: K.347, R.350
Ligand excluded by PLIPIOD.25: 2 residues within 4Å:- Chain A: I.419, R.423
Ligand excluded by PLIPIOD.26: 3 residues within 4Å:- Chain A: K.374, R.375
- Ligands: IOD.43
Ligand excluded by PLIPIOD.27: 1 residues within 4Å:- Chain A: P.248
Ligand excluded by PLIPIOD.28: 2 residues within 4Å:- Chain A: D.209, K.393
Ligand excluded by PLIPIOD.29: 3 residues within 4Å:- Chain A: K.351, E.354, Q.355
Ligand excluded by PLIPIOD.30: 3 residues within 4Å:- Chain A: F.232, P.240, R.246
Ligand excluded by PLIPIOD.31: 1 residues within 4Å:- Chain A: R.281
Ligand excluded by PLIPIOD.32: 1 residues within 4Å:- Chain A: R.325
Ligand excluded by PLIPIOD.33: 2 residues within 4Å:- Chain A: M.441
- Chain C: R.84
Ligand excluded by PLIPIOD.34: 2 residues within 4Å:- Chain A: R.413, Q.414
Ligand excluded by PLIPIOD.35: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.36: 1 residues within 4Å:- Chain A: R.447
Ligand excluded by PLIPIOD.37: 1 residues within 4Å:- Chain A: F.408
Ligand excluded by PLIPIOD.38: 2 residues within 4Å:- Chain A: R.423, S.453
Ligand excluded by PLIPIOD.39: 2 residues within 4Å:- Chain A: C.452, S.453
Ligand excluded by PLIPIOD.40: 1 residues within 4Å:- Chain A: R.350
Ligand excluded by PLIPIOD.41: 2 residues within 4Å:- Chain A: Q.81, L.82
Ligand excluded by PLIPIOD.42: 3 residues within 4Å:- Chain A: R.281, Q.282, N.283
Ligand excluded by PLIPIOD.43: 3 residues within 4Å:- Chain A: T.192, K.374
- Ligands: IOD.26
Ligand excluded by PLIPIOD.44: 1 residues within 4Å:- Chain A: Q.414
Ligand excluded by PLIPIOD.45: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.46: 2 residues within 4Å:- Chain A: R.127
- Ligands: IOD.14
Ligand excluded by PLIPIOD.47: 4 residues within 4Å:- Chain A: T.47
- Chain B: T.47
- Ligands: IOD.23, IOD.79
Ligand excluded by PLIPIOD.50: 5 residues within 4Å:- Chain B: N.214, V.215, W.324
- Chain D: R.33, W.34
Ligand excluded by PLIPIOD.51: 5 residues within 4Å:- Chain B: N.236, R.270, I.431, T.432, T.433
Ligand excluded by PLIPIOD.52: 1 residues within 4Å:- Chain B: W.402
Ligand excluded by PLIPIOD.53: 2 residues within 4Å:- Chain B: N.345, K.351
Ligand excluded by PLIPIOD.54: 4 residues within 4Å:- Chain B: Q.89, F.101
- Chain F: E.5, H.6
Ligand excluded by PLIPIOD.55: 1 residues within 4Å:- Chain B: R.325
Ligand excluded by PLIPIOD.56: 4 residues within 4Å:- Chain B: R.127, E.130
- Ligands: HEM.49, IOD.78
Ligand excluded by PLIPIOD.57: 2 residues within 4Å:- Chain B: P.12, R.49
Ligand excluded by PLIPIOD.58: 1 residues within 4Å:- Chain B: P.331
Ligand excluded by PLIPIOD.59: 2 residues within 4Å:- Chain B: A.97, R.143
Ligand excluded by PLIPIOD.60: 2 residues within 4Å:- Chain B: P.186, P.191
Ligand excluded by PLIPIOD.61: 4 residues within 4Å:- Chain B: V.208, D.209, K.393
- Ligands: NAG-NAG-BMA-MAN-MAN-FUC.6
Ligand excluded by PLIPIOD.62: 2 residues within 4Å:- Chain B: Q.297
- Ligands: NAG-NAG.5
Ligand excluded by PLIPIOD.63: 2 residues within 4Å:- Chain B: R.378
- Ligands: IOD.80
Ligand excluded by PLIPIOD.64: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.65: 1 residues within 4Å:- Chain B: R.163
Ligand excluded by PLIPIOD.66: 3 residues within 4Å:- Chain B: G.329, L.330, P.331
Ligand excluded by PLIPIOD.67: 1 residues within 4Å:- Chain B: Q.228
Ligand excluded by PLIPIOD.68: 2 residues within 4Å:- Chain B: K.374
- Ligands: IOD.81
Ligand excluded by PLIPIOD.69: 1 residues within 4Å:- Chain B: N.27
Ligand excluded by PLIPIOD.70: 2 residues within 4Å:- Chain B: R.350, E.354
Ligand excluded by PLIPIOD.71: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.72: 3 residues within 4Å:- Chain B: R.423, C.452, S.453
Ligand excluded by PLIPIOD.73: 1 residues within 4Å:- Chain B: R.246
Ligand excluded by PLIPIOD.74: 2 residues within 4Å:- Chain B: I.419, R.423
Ligand excluded by PLIPIOD.75: 2 residues within 4Å:- Ligands: NAG-NAG.5, NAG-NAG.5
Ligand excluded by PLIPIOD.76: 1 residues within 4Å:- Chain B: R.251
Ligand excluded by PLIPIOD.77: 1 residues within 4Å:- Chain B: R.375
Ligand excluded by PLIPIOD.78: 1 residues within 4Å:- Ligands: IOD.56
Ligand excluded by PLIPIOD.79: 1 residues within 4Å:- Ligands: IOD.47
Ligand excluded by PLIPIOD.80: 2 residues within 4Å:- Chain D: R.84
- Ligands: IOD.63
Ligand excluded by PLIPIOD.81: 4 residues within 4Å:- Chain B: T.192, K.196, K.374
- Ligands: IOD.68
Ligand excluded by PLIPIOD.82: 4 residues within 4Å:- Chain B: D.235, N.236, M.241, R.270
Ligand excluded by PLIPIOD.85: 5 residues within 4Å:- Chain A: N.214, V.215, W.324
- Chain C: R.33, W.34
Ligand excluded by PLIPIOD.86: 1 residues within 4Å:- Chain C: R.72
Ligand excluded by PLIPIOD.87: 3 residues within 4Å:- Chain A: I.48
- Chain B: R.211
- Chain C: A.37
Ligand excluded by PLIPIOD.88: 3 residues within 4Å:- Chain B: R.326, N.360
- Chain C: R.20
Ligand excluded by PLIPIOD.89: 2 residues within 4Å:- Chain C: G.52, P.59
Ligand excluded by PLIPIOD.90: 2 residues within 4Å:- Chain C: C.3
- Chain D: E.40
Ligand excluded by PLIPIOD.91: 0 residues within 4Å:- (No contacts)
Ligand excluded by PLIPIOD.92: 1 residues within 4Å:- Chain C: P.59
Ligand excluded by PLIPIOD.93: 1 residues within 4Å:- Chain C: Q.6
Ligand excluded by PLIPIOD.94: 3 residues within 4Å:- Chain A: R.211
- Chain B: I.48
- Chain D: A.37
Ligand excluded by PLIPIOD.95: 2 residues within 4Å:- Chain D: G.52, P.59
Ligand excluded by PLIPIOD.96: 2 residues within 4Å:- Chain B: P.276
- Chain D: Q.82
Ligand excluded by PLIPIOD.97: 1 residues within 4Å:- Chain D: C.3
Ligand excluded by PLIPIOD.98: 1 residues within 4Å:- Chain A: N.74
Ligand excluded by PLIPIOD.99: 1 residues within 4Å:- Chain F: K.40
Ligand excluded by PLIP- 2 x CA: CALCIUM ION(Non-covalent)
CA.48: 5 residues within 4Å:- Chain A: T.56, F.58, D.60, S.62
- Chain C: D.98
5 PLIP interactions:3 interactions with chain A, 2 interactions with chain C- Metal complexes: A:F.58, A:D.60, A:S.62, C:D.98, C:D.98
CA.83: 5 residues within 4Å:- Chain B: T.56, F.58, D.60, S.62
- Chain D: D.98
5 PLIP interactions:1 interactions with chain D, 4 interactions with chain B- Metal complexes: D:D.98, B:T.56, B:F.58, B:D.60, B:S.62
- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Covalent)
HEM.49: 23 residues within 4Å:- Chain B: R.127, E.130, M.131, T.217, F.220, R.221, Y.222, G.223, H.224, I.227, F.253, F.295, L.305, L.308, R.312
- Chain D: M.89, G.92, Q.93, D.96, D.100, F.101, T.102
- Ligands: IOD.56
18 PLIP interactions:15 interactions with chain B, 3 interactions with chain D,- Hydrophobic interactions: B:E.130, B:M.131, B:F.220, B:R.221, B:Y.222, B:I.227, B:F.253, B:F.295, B:L.305, B:L.305, D:Q.93, D:Q.93
- Water bridges: B:R.221
- Salt bridges: B:R.127, B:R.221, B:R.312
- Metal complexes: B:H.224
- Hydrogen bonds: D:T.102
HEM.84: 22 residues within 4Å:- Chain A: R.127, E.130, M.131, T.217, F.220, R.221, G.223, H.224, I.227, F.253, F.295, L.305, L.308, R.312
- Chain C: M.89, G.92, Q.93, D.96, D.100, F.101, T.102
- Ligands: IOD.14
24 PLIP interactions:6 interactions with chain C, 18 interactions with chain A,- Hydrophobic interactions: C:Q.93, C:Q.93, C:D.96, A:E.130, A:M.131, A:F.220, A:R.221, A:I.227, A:F.253, A:F.295, A:L.305, A:L.305
- Hydrogen bonds: C:D.100, C:T.102, C:T.102
- Water bridges: A:R.127, A:R.127, A:T.217, A:R.221, A:R.221
- Salt bridges: A:R.127, A:R.221, A:R.312
- Metal complexes: A:H.224
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Leitgeb, U. et al., Halide binding by myeloperoxidase is regulated by access channel dynamics and charge interactions. Int.J.Biol.Macromol. (2025)


- Release Date
- 2025-10-15
- Peptides
- Myeloperoxidase heavy chain: AB
Myeloperoxidase light chain: CD
Myeloperoxidase inhibitor SPIN: EF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
DC
AD
CE
EF
F
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.63 Å
- Oligo State
- hetero-2-2-2-mer
- Ligands
- 4 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- NAG- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 89 x IOD: IODIDE ION(Non-functional Binders)
- 2 x CA: CALCIUM ION(Non-covalent)
- 2 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Leitgeb, U. et al., Halide binding by myeloperoxidase is regulated by access channel dynamics and charge interactions. Int.J.Biol.Macromol. (2025)


- Release Date
- 2025-10-15
- Peptides
- Myeloperoxidase heavy chain: AB
Myeloperoxidase light chain: CD
Myeloperoxidase inhibitor SPIN: EF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
DC
AD
CE
EF
F